- More than 232 attendees, approved 3 agendas including approval of financial statement
- CEO Tae Han Kim said “challenge to become the ‘Game Changer’ in global CMO market”
Samsung Biologics (CEO: Tae Han Kim) held the 6th general meeting of shareholders at Incheon Global Campus in Songdo, Incheon at 9am Friday. It was the first meeting after the company was listed on KOSPI market November of last year.
More than 232 shareholders attended the event. The meeting went along in a good mood with shareholder’s appreciation for the efforts of the company’s employees as the share price continued to rise after the listing in November of last year.
In the meeting, total of 3 agendas, including the approval of the 6th financial statement, appointment of Tae Han Kim as an internal director, and the approval of remuneration limit of internal directors, approved. Tae Han Kim was re-elected in 2014 and 2017 after he first elected as the CEO with the founding of the company in 2011.
Tae Han Kim said “Despite the difficult situation, biopharmaceutical market managed to maintain a high growth. This phenomenon can be explained by the ‘4-Ups’ (Age-up, Disease-up, Knowledge/Science-up, and Wealth-up). Samsung Biologics expects CMO demand to grow sharply amid this quantitative growth”.
In addition, he said “Plant 1, which began commercial operation in 2015, has been recorded a surplus in operating income since last year, Plant 2 is ramping up to prepare for full production, and Plant 3 has recorded construction progress of 70% and will be mechanically complete by Q4 this year”.
He also stated the company’s new goal that “Samsung Biologics will challenge to become a ‘Game Changer’ that bring up the share of CMO production in the biopharmaceutical market from 25% to 50%”, he added “Samsung Biologics will make sure to achieve top client satisfaction and innovation in productivity through ‘Breakthrough-21’ management innovation activities.”
Lastly, Kim said “As a newly listed public company, Samsung Biologics will contribute to national economic development through transparent and ethical management, and to our national and local community though creating high-value-adding jobs”.
- More than 232 attendees, approved 3 agendas including approval of financial statement
- CEO Tae Han Kim said “challenge to become the ‘Game Changer’ in global CMO market”
Samsung Biologics (CEO: Tae Han Kim) held the 6th general meeting of shareholders at Incheon Global Campus in Songdo, Incheon at 9am Friday. It was the first meeting after the company was listed on KOSPI market November of last year.
More than 232 shareholders attended the event. The meeting went along in a good mood with shareholder’s appreciation for the efforts of the company’s employees as the share price continued to rise after the listing in November of last year.
In the meeting, total of 3 agendas, including the approval of the 6th financial statement, appointment of Tae Han Kim as an internal director, and the approval of remuneration limit of internal directors, approved. Tae Han Kim was re-elected in 2014 and 2017 after he first elected as the CEO with the founding of the company in 2011.
Tae Han Kim said “Despite the difficult situation, biopharmaceutical market managed to maintain a high growth. This phenomenon can be explained by the ‘4-Ups’ (Age-up, Disease-up, Knowledge/Science-up, and Wealth-up). Samsung Biologics expects CMO demand to grow sharply amid this quantitative growth”.
In addition, he said “Plant 1, which began commercial operation in 2015, has been recorded a surplus in operating income since last year, Plant 2 is ramping up to prepare for full production, and Plant 3 has recorded construction progress of 70% and will be mechanically complete by Q4 this year”.
He also stated the company’s new goal that “Samsung Biologics will challenge to become a ‘Game Changer’ that bring up the share of CMO production in the biopharmaceutical market from 25% to 50%”, he added “Samsung Biologics will make sure to achieve top client satisfaction and innovation in productivity through ‘Breakthrough-21’ management innovation activities.”
Lastly, Kim said “As a newly listed public company, Samsung Biologics will contribute to national economic development through transparent and ethical management, and to our national and local community though creating high-value-adding jobs”.
Share article
Related Content